Can Payers and the Drug Industry Agree on Real Value?

Posted by Ed Schoonveld on Mon, Mar 23, 2015

Recent developments in the pharmaceutical industry give the strong impression that both payers and industry are struggling to understand what represents “value” to our customers. The epicenter of many value discussions has been the United Kingdom, where three years of intensive discussions have sought to quantify the value of prescription drugs through Value-Based Pricing (VBP). However, the discussions halted abruptly over a rejection of the concept during a public consultation process, leaving the health economist community wondering what is next.


>
Read More

Questions (and a Few Answers) Arise as the FDA Approves First Biosimilar

Posted by Ed Schoonveld on Mon, Mar 16, 2015

We live in interesting times. We just saw the approval of Zarxio, the first U.S. biosimilar product of Neupogen (filgrastim). What it means for both products is still uncertain, as U.S. rules for biosimilars are still evolving. Key questions have been the convention of proprietary names for biosimilars and the interchangeability between original and biosimilar. These two questions may be an important driver of views and actions from payers and prescribers.


>
Read More

Are Global Markets Free-Riding on the United States?

Posted by Ed Schoonveld on Mon, Feb 23, 2015

In reaction to my recent blog on the cost of drug development, Peter raised the “global free-riding” problem and asked for my perspective. The global free-riding problem is the perception that the United States is subsidizing drugs for the rest of the world due to high drug prices in the United States compared with other countries.


>
Read More

Is Express Scripts the New Robin Hood?

Posted by Ed Schoonveld on Fri, Jan 30, 2015

Express Scripts (ESI) has been drawing a lot of publicity recently over its strong stance on drug pricing and willingness to engage in exclusive formulary listing agreements for high-cost specialty drugs. Particularly with respect to hepatitis C drugs, ESI initiated an exclusive contract with AbbVie’s Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets,) which came second to market after Gilead’s Sovaldi (sofosbuvir) and Harvoni (sofosbuvir and ledipasvir).


>
Read More

Top Three Issues in Market Access?

Posted by Ed Schoonveld on Wed, Jan 28, 2015

The prescription drug industry is under a lot of change with the Affordable Care Act, heavy drug pricing debates for oncology and hepatitis C, and many system reforms in Europe.


>
Read More